Travere Therapeutics, Inc. (NASDAQ: TVTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $15.00 to $18.00. They now have a "buy" rating on the stock.
Here's What Key Metrics Tell Us About Travere (TVTX) Q1 Earnings [Yahoo! Finance]
Travere Therapeutics Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Travere Therapeutics Reports First Quarter 2024 Financial Results